期刊文献+

甲状腺乳头状癌BRAFV600E基因突变的研究 被引量:5

下载PDF
导出
摘要 目的研究甲状腺乳头状癌(PTC)BRAFV600E基因的突变情况,分析突变与临床特点之间的关系。方法提取42例甲状腺乳头状癌石蜡标本DNA,对BRAF基因第15外显子进行聚合酶链反应(PCR),产物进行直接基因测序。结果在42例PTC中,检测到19例存在BRAFV600E突变。突变患者组的年龄更轻,而突变组与无突变组间肿瘤大小、是否多灶性、包膜浸润、淋巴结转移、肿瘤分期和组织亚型差异均没有统计学意义。结论BRAF基因突变可能与甲状腺乳头状癌的发生有关。
出处 《现代实用医学》 2009年第12期1296-1297,1306,F0002,共4页 Modern Practical Medicine
  • 相关文献

参考文献15

  • 1Davies L,Welch HG.lncreasing Incidence of Thyroid Cancer in the United States, 1973-2002[J]. JAMA,2006,(18)295:2164-2167.
  • 2Ciampi R, Nikiforov YE. RET/PTC rear rangernents and BRAF mutations in thy- roid tumorigenesis[J]. Endocrinology, 2007,148(3):936-941.
  • 3Xing M. BRAF mutation in papillary thyroid cancer: Pathogenicd role, molecular bases, and clinical impliations[J]. Endocr Rev,2007, 28(7):742-762.
  • 4Hedinger C, Williams ED, Sobin LH. The Wl-IO histological classification of thyroid tumors: a commentary on the second edition[J]. Cancer ,1989, 63:908-911.
  • 5Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fineneedle aspiration diagnosis of papillary thyroid carcinoma[J]. J Clin Endocrinol Metab,2004,89(10):5175-5180.
  • 6牛卫,罗月球,陈丽荣.甲状腺乳头状癌BRAF基因突变及表达的临床意义研究[J].实用肿瘤杂志,2008,23(6):519-523. 被引量:11
  • 7米志宽,王爱红,赵振峰,李小记,惠起源.甲状腺乳头状癌中BRAF^(V600E)点突变的研究[J].陕西医学杂志,2008,37(11):1471-1473. 被引量:5
  • 8Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between BRAFV600E muta- tion and clinico-pathologic parameters in papillary, thyroid carcinoma: data from a multicentric Italian study and review of the literature[J]. Endocr Relat Cancer, 2006:13(2):455-464.
  • 9Elisei R, Ugolini C, Viola D, et al. BRAF (V600E) mutation and outcome of patients vcith papillary thyroid carcinoma: a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008,93 ( 10):3943 -3949.
  • 10Lupi C, Giannini R, Ugolini C, el al. Association ofBRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillae, thyroid carcinoma[J]. J Clin Endocrinol Melab.2007, 92(1 1):4085-4090.

二级参考文献27

  • 1Kimura ET, Nikiforova MN, Zhu ZW, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma [J]. Cancer Res, 2003,63(7) : 1454 -1457.
  • 2Salvatore G,Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma [J]. J Clin Endocrinol Metab, 2004,89 (10) : 5157-5180.
  • 3Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF,RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer [J]. Oncogene, 2004,23 (44) : 7436-7440.
  • 4Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers [J]. Clin Endocrinol, 2004,61 (2) : 239 - 243.
  • 5Xing MZ,Cohen Y,Mambo E,et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis [J]. Cancer Res, 2004, 64 (5) : 1664- 1668.
  • 6Cohen Y, Rosenbaum E,Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: A potential application for the preoperative assessment of thyroid nodules [J]. Clin Cancer Res,2004,10(8):2761-2765.
  • 7Xu XL,Quiros RM,Gattuso P,et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines [J]. Cancer Res, 2003,63 (15) : 4561 - 4567.
  • 8Oler G, Ebina KN, Michaluart P, et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis [J]. Clin Endocrinol, 2005,62 (4) : 509-511.
  • 9Xing MZ, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer [J]. J Clin Endocrinol Metab, 2005,90(12) : 6373- 6379.
  • 10Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis,especially in BRAF^v600E mutation-prevalent area [J]. Clin Endocrinol,2006,65(5) :660-666.

共引文献12

同被引文献88

引证文献5

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部